<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200603047648N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-07-13</date_registration>
      <primary_sponsor>Karaj University of Medical Sciences</primary_sponsor>
      <public_title>Mesoprostol and Dilapen in the preparation of the cervix for abortion</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of Misoprostol and Diplen with Misoprostol in cervical priming in the first and second trimesters</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>196</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48736</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, random allocation of individuals to two groups of intervention and current treatment was performed using Balanced bloch randomization technique. Using R software to generate random number chains 1 to 6 (the number of possible states for placement in blocks) Until the volume of the sample was reached. Preparation of random allocation sequences of individuals and placing them in sealed envelopes (sealed) and numbered with a 5-digit serial number by the third person who plays a role in designing the study. Has not, has been done, Blinding description: In the treatment group, in addition to receiving vaginal diazepam mesoprostol, it is vaginally placed by a specialist doctor, and in the control group, only mesoprostol is received. After the procedure, patients will be examined by 2 blind researchers who do not know to whom dilapen is placed. Who has only used misoprostol. Patients will be examined by two researchers in terms of postoperative complications. The patient will then be hospitalized for side effects after surgery and the consequences of the procedure. The patient's opinion is checked by a student (specific to this task) that the student does not know who received the diplopen and who did not receive it and records all the consequences. In fact, neither the researcher nor the evaluator of the consequences of how patients are divided.</study_design>
      <phase>3</phase>
      <hc_freetext>Medical abortion in first and second trimester.</hc_freetext>
      <i_freetext>Intervention 1: Control group: Control group: In the control group, to prepare the cervix, 400 micrograms of misoprostol will be placed vaginally by a gynecologist 4 hours before surgery. Mesoprostol is an analogue of prostaglandin E1, which is the best option for cervical preparation studies in terms of speed, function and cost. Intervention 2: Intervention group: Intervention group: In this group, to prepare the cervix, 24 hours before the surgery, a diplopene is placed vaginally by the obstetrician and gynecologist for the patient. The cervix becomes vaginal). 4 hours before surgery, 400 micrograms of misoprostol will be vaginally placed by a gynecologist (exactly as done for the control group). The synergistic effect of the two can be examined together.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Bita Badehnoosh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kamali hospital ,Kamali Ave, shohada sq, Beheshti blvd</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4156853445</zip>
        <telephone>+98 26 4158 6658</telephone>
        <email>badehnoosh@abzums.ac.ir</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Bita Badehnoosh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Alborz university of medical sciences , Saffarian Alley , Golshahr</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4156853445</zip>
        <telephone>0098 26 4158665</telephone>
        <email>badehnoosh@abzums.ac.ir</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age over 18 years for mothers
Less or equal pregnancy age 24 weeks based on (LMP) and ultrasound of the first 3 months of pregnancy
Patient satisfaction to participate in the study
Legal permission for abortion is from the relevant authorities</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Patients under 18 years of age
Contraindications to the use of misoprostol (drug allergy, active asthma, heart disease, renal failure or glaucoma)
Active genital infection
Structural disorders of the uterus and bladder
Cervical cancer
History of cervical surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O04.80</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>(Induced) termination of pregnancy with unspecified complications</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: Control group: In the control group, to prepare the cervix, 400 micrograms of misoprostol will be placed vaginally by a gynecologist 4 hours before surgery. Mesoprostol is an analogue of prostaglandin E1, which is the best option for cervical preparation studies in terms of speed, function and cost.</i_keyword>
      <i_keyword>Intervention group: Intervention group: In this group, to prepare the cervix, 24 hours before the surgery, a diplopene is placed vaginally by the obstetrician and gynecologist for the patient. The cervix becomes vaginal). 4 hours before surgery, 400 micrograms of misoprostol will be vaginally placed by a gynecologist (exactly as done for the control group). The synergistic effect of the two can be examined together</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Cervical dilatation rate. Timepoint: Before surgery and after general anesthesia. Method of measurement: Examination by a specialist.</prim_outcome>
      <prim_outcome>Feeling sick. Timepoint: Before surgery and after general anesthesia. Method of measurement: Examination by a specialist doctor based on a five-digit criterion (without discomfort, with discomfort, relatively uncomfortable, very uncomfortable, unbearable).</prim_outcome>
      <prim_outcome>Servicing preparation time. Timepoint: After receiving the drug until the start of surgery. Method of measurement: Examination by a specialist.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Side effects( include vaginal pain, pressure on the bladder, diarrhea and vaginal bleeding, and incomplete miscarriage.). Timepoint: Before general anesthesia, after the procedure and the patient regained consciousness. Method of measurement: Examination by a specialist doctor, ultrasound (if you have symptoms in favor of incomplete abortion once before discharge).</sec_outcome>
      <sec_outcome>Cervical consistency. Timepoint: Before surgery and after general anesthesia. Method of measurement: Examination by a specialist doctor based on three-digit criteria (according to the surgeon, soft, medium, hard).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Karaj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-05-26</approval_date>
        <contact_name>Ethics committee of Alborz University Of medical Sciences</contact_name>
        <contact_address>Saffarian Alley, Golshahr Karaj Alborz Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
